BFRI - Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation

• German biopharmaceutical company Biofrontera ( NASDAQ: BFRI ) on Tuesday said it had been granted a notice of allowance by the U.S. patent body for a patent covering a nanoemulsion formulation.
• The U.S. Patent and Trademark Office (USPTO) granted patent application number 12/520,759 titled "Nanoemulsion Formulation with Improved Stability and Cell Penetration," BFRI said in a statement .
• The company said it has an exclusive license to market and sell Ameluz in the U.S., which is an FDA-approved drug to treat potentially cancerous skin growths and uses the technology covered by the patent.
• BFRI also said it had been granted a special designation from the USPTO that enabled an expedited review of a recently submitted patent application relating to illumination protocols for the treatment of skin diseases with photodynamic therapy, which uses a drug activated by light to kill diseases cells.
• BFRI stock +1.7% to $1.21 in morning trading.

For further details see: